Resmetirom for Steatotic Liver Disease: Does Data Support Widespread Use?

Area of Science:

• Hepatology
• Endocrinology
• Pharmacology

Background:

• Metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis is an aggressive liver disease.
• Progression to cirrhosis and its complications pose a serious health risk.
• Current treatment options for advanced MASH are limited.

Purpose of the Study:

• To review the clinical development program of resmetirom, a thyroid hormone receptor beta agonist.
• To discuss the role of noninvasive tests in patient selection and monitoring for resmetirom therapy.
• To explore the real-world utility and application of resmetirom in managing MASH.

Main Methods:

• Review of the MAESTRO clinical trial data.
• Analysis of resmetirom's mechanism of action as a liver-directed thyroid hormone receptor beta agonist.
• Discussion of noninvasive diagnostic and monitoring tools for MASH.

Main Results:

• Resmetirom demonstrated reasonable safety and efficacy in the MAESTRO trial.
• Histological assessment showed MASH resolution and fibrosis regression with resmetirom treatment.
• The drug has received accelerated FDA approval for MASH with significant fibrosis.

Conclusions:

• Resmetirom represents a significant advancement in MASH treatment.
• Noninvasive tests are crucial for optimizing patient selection and monitoring resmetirom therapy.
• Real-world data will further elucidate the long-term benefits and challenges of resmetirom use.